Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 1, 20-37, January 2007; doi:10.1634/theoncologist.12-1-20
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayat, M. J.
Right arrow Articles by Edwards, B. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayat, M. J.
Right arrow Articles by Edwards, B. K.

Epidemiology and Population Studies: SEER Series

Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program

Matthew J. Hayat, Nadia Howlader, Marsha E. Reichman, Brenda K. Edwards

Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA

Key Words. Cancer statistics • Incidence • Lifetime risk • Multiple primaries • Survival • SEER

Correspondence: Brenda K. Edwards, Ph.D., Division of Cancer Control and Population Sciences, National Cancer Institute, 6116 Executive Blvd., Suite 504, Bethesda, Maryland 20892-8315, USA. Telephone: 301-496-8506; Fax: 301-480-4077; e-mail: edwardsb{at}mail.nih.gov

An overview of cancer statistics and trends for selected cancers and all sites combined are given based on data from the Surveillance, Epidemiology, and End Results Program. Median age at diagnosis for all sites combined shows a 2-year increase from 1974 through 1978 to 1999 through 2003. Changes in cancer incidence rates from 1975 through 2003 are summarized by annual percent change for time periods determined by joinpoint regression analysis. After initial stability (1975–1979), incidence rates in women for all cancer sites combined increased from 1979 through 2003, although the rate of increase has recently slowed. For men, initial increases in all cancer sites combined (1975–1992) are followed by decreasing incidence rates (1992–1995) and stable trends from 1995 through 2003. Female thyroid cancer shows continued increasing incidence rates from 1981 through 2003. Blacks have the highest incidence and mortality rates for men and women for all cancer sites combined. Based on 2001 through 2003 data, the likelihood of developing cancer during one’s lifetime is approximately one in two for men and one in three for women. Five-year relative survival for all stages combined (1996–2002) ranges from 16% for lung to 100% for prostate cancer patients. Cancer survival varies by stage of disease and race, with lower survival in blacks compared with whites. The risk of developing subsequent multiple primary cancers varies from 1% for an initial liver primary diagnosis to 16% for initial bladder cancer primaries. The impact on the future U.S. cancer burden is estimated based on the growing and aging U.S. population. The number of new cancer patients is expected to more than double from 1.36 million in 2000 to almost 3.0 million in 2050.




This article has been cited by other articles:


Home page
 Journal of the American Animal Hospital AssociationHome page
R. B. Rebhun and D. H. Thamm
Multiple Distinct Malignancies in Dogs: 53 Cases
J. Am. Anim. Hosp. Assoc., January 1, 2010; 46(1): 20 - 30.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Medical OncologyHome page
J. A. Sipos and M. H. Shah
Review: Thyroid cancer: emerging role for targeted therapies
Therapeutic Advances in Medical Oncology, January 1, 2010; 2(1): 3 - 16.
[Abstract] [PDF]

Home page
 Anticancer ResHome page
J. GRINIATSOS, C. TSIGRIS, M. KANAKIS, G. KALTSAS, O. MICHAIL, N. DIMITRIOU, G. ARGYRAKOPOULOU, I. DELLADETSIMA, V. KYRIAKOU, V. SYRIOU, et al.
Increased Incidence of Papillary Thyroid Cancer Detection among Thyroidectomies in Greece between 1991 and 2006
Anticancer Res, December 1, 2009; 29(12): 5163 - 5169.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Schlaberg, D. J. Choe, K. R. Brown, H. M. Thaker, and I. R. Singh
XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors
PNAS, September 22, 2009; 106(38): 16351 - 16356.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Ray and H. L. Kindler
Malignant Pleural Mesothelioma: An Update on Biomarkers and Treatment
Chest, September 1, 2009; 136(3): 888 - 896.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Iverson, G. Larson, C. Lai, L.-T. Yeh, C. Dadson, P. Weingarten, T. Appleby, T. Vo, A. Maderna, J.-M. Vernier, et al.
RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
Cancer Res., September 1, 2009; 69(17): 6839 - 6847.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. H. Cazares, D. Troyer, S. Mendrinos, R. A. Lance, J. O. Nyalwidhe, H. A. Beydoun, M. A. Clements, R. R. Drake, and O. J. Semmes
Imaging Mass Spectrometry of a Specific Fragment of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase 2 Discriminates Cancer from Uninvolved Prostate Tissue
Clin. Cancer Res., September 1, 2009; 15(17): 5541 - 5551.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Pajer, V. Karafiat, V. Pecenka, D. Prukova, J. Dudlova, J. Plachy, P. Kasparova, and M. Dvorak
Industasis, a Promotion of Tumor Formation by Nontumorigenic Stray Cells
Cancer Res., June 1, 2009; 69(11): 4605 - 4612.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
A. Y. Giuffrida, J. E. Burgueno, L. G. Koniaris, J. C. Gutierrez, R. Duncan, and S. P. Scully
Chondrosarcoma in the United States (1973 to 2003): An Analysis of 2890 Cases from the SEER Database
J. Bone Joint Surg. Am., May 1, 2009; 91(5): 1063 - 1072.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. de Azambuja, M. Paesmans, M. Beauduin, A. Vindevoghel, N. Cornez, C. Finet, F. Ries, M. T. Closon-Dejardin, J. Kerger, P. Gobert, et al.
Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study
J. Clin. Oncol., February 10, 2009; 27(5): 720 - 725.
[Abstract] [Full Text] [PDF]

Home page
 Am J Clin PatholHome page
R. Mazzucchelli, F. Barbisan, M. Scarpelli, A. Lopez-Beltran, T. H. van der Kwast, L. Cheng, and R. Montironi
Is Incidentally Detected Prostate Cancer in Patients Undergoing Radical Cystoprostatectomy Clinically Significant?
Am J Clin Pathol, February 1, 2009; 131(2): 279 - 283.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Karan, J. Holzbeierlein, and J. B. Thrasher
Macrophage Inhibitory Cytokine-1: Possible Bridge Molecule of Inflammation and Prostate Cancer
Cancer Res., January 1, 2009; 69(1): 2 - 5.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G. Sassolas, Z. Hafdi-Nejjari, L. Remontet, N. Bossard, A. Belot, N. Berger-Dutrieux, M. Decaussin-Petrucci, C. Bournaud, J. L. Peix, J. Orgiazzi, et al.
Thyroid cancer: is the incidence rise abating?
Eur. J. Endocrinol., January 1, 2009; 160(1): 71 - 79.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Dawood, K. Broglio, A. M. Gonzalez-Angulo, A. U. Buzdar, G. N. Hortobagyi, and S. H. Giordano
Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer
J. Clin. Oncol., October 20, 2008; 26(30): 4891 - 4898.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Azim, M. Costantini-Ferrando, and K. Oktay
Safety of Fertility Preservation by Ovarian Stimulation With Letrozole and Gonadotropins in Patients With Breast Cancer: A Prospective Controlled Study
J. Clin. Oncol., June 1, 2008; 26(16): 2630 - 2635.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Wheatley-Price, K. Ding, L. Seymour, G. M. Clark, and F. A. Shepherd
Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
J. Clin. Oncol., May 10, 2008; 26(14): 2350 - 2357.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Leyvraz, S. Pampallona, G. Martinelli, F. Ploner, L. Perey, S. Aversa, S. Peters, P. Brunsvig, A. Montes, A. Lange, et al.
A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial
J Natl Cancer Inst, April 16, 2008; 100(8): 533 - 541.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. Marur and A. A. Forastiere
Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment
Mayo Clin. Proc., April 1, 2008; 83(4): 489 - 501.
[Abstract] [Full Text] [PDF]

Home page
 radtechHome page
J. S LEGG
Bladder Cancer Imaging
Radiol. Technol., March 1, 2008; 79(4): 333 - 346.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
F. Demichelis and M. A Rubin
TMPRSS2-ETS fusion prostate cancer: biological and clinical implications
J. Clin. Pathol., November 1, 2007; 60(11): 1185 - 1186.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement